Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist that is under development for the treatment of type 2 diabetes. The efficacy and safety of once-weekly tirzepatide as compared with semaglutide, a selective GLP-1 receptor agonist, are unknown. METHODS: In an open-label, 40-week, phase 3 trial, we randomly assigned 1879 patients, in a 1:1:1:1 ratio, to receive tirzepatide at a dose of 5 mg, 10 mg, or 15 mg or semaglutide at a dose of 1 mg. At baseline, the mean glycated hemoglobin level was 8.28%, the mean age 56.6 years, and the mean weight 93.7 kg. The primary end point was the change in the glycated hemoglobin level from baseline to 40 weeks. RESULTS: The estimated mean change from baseline in the glycated hemoglobin level was -2.01 percentage points, -2.24 percentage points, and -2.30 percentage points with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and -1.86 percentage points with semaglutide; the estimated differences between the 5-mg, 10-mg, and 15-mg tirzepatide groups and the semaglutide group were -0.15 percentage points (95% confidence interval [CI], -0.28 to -0.03; P = 0.02), -0.39 percentage points (95% CI, -0.51 to -0.26; P<0.001), and -0.45 percentage points (95% CI, -0.57 to -0.32; P<0.001), respectively. Tirzepatide at all doses was noninferior and superior to semaglutide. Reductions in body weight were greater with tirzepatide than with semaglutide (least-squares mean estimated treatment difference, -1.9 kg, -3.6 kg, and -5.5 kg, respectively; P<0.001 for all comparisons). The most common adverse events were gastrointestinal and were primarily mild to moderate in severity in the tirzepatide and semaglutide groups (nausea, 17 to 22% and 18%; diarrhea, 13 to 16% and 12%; and vomiting, 6 to 10% and 8%, respectively). Of the patients who received tirzepatide, hypoglycemia (blood glucose level, <54 mg per deciliter) was reported in 0.6% (5-mg group), 0.2% (10-mg group), and 1.7% (15-mg group); hypoglycemia was reported in 0.4% of those who received semaglutide. Serious adverse events were reported in 5 to 7% of the patients who received tirzepatide and in 3% of those who received semaglutide. CONCLUSIONS: In patients with type 2 diabetes, tirzepatide was noninferior and superior to semaglutide with respect to the mean change in the glycated hemoglobin level from baseline to 40 weeks. (Funded by Eli Lilly; SURPASS-2 ClinicalTrials.gov number, NCT03987919.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationDavies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Self-citationGlucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Self-citationCoskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882
Self-citationFrias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815
Self-citationPratley, R. E., Aroda, V. R., Lingvay, I., Lüdemann, J., Andreassen, C., Navarria, A., & Viljoen, A. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30024-x · Cited by 790
Sorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745
Ahmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R. (2018) · Diabetes Care · doi:10.2337/dc17-0417 · Cited by 596
Cited by
Items 1,601–1,700 of 2,039
Tirzepatide cardiovascular benefits and adverse events assessment: a Bayesian network meta-analysisPreprint
gong, X., cheng, P., han, Y., li, Q., Song, C., & Zhao, Y. (2024) · Research Square · doi:10.21203/rs.3.rs-4159026/v1
FATORES QUE INFLUENCIAM NA PREMATURIDADE
Carneiro, C. R. D. N., Reis, C. C. C., Dias, R. A., Sales, E. Q., Ferreira, T. P. A., Silva, P. S. L. E., Costa, P. N., Soares, J. B., Reis, M. C. P., Fernandes, L., et al. (2024) · doi:10.22533/at.ed.8022401043
de Freitas, S. S., Alves, J. D. L., da Silva, W. L. S., Paulino, B. D. S., Prado, N. S., de Arruda, M. A., Amancio, S. R. F., de Barros, C. F. E., Bezerra, A. M. F. D. A., de Souza, F. R., et al. (2024) · doi:10.22533/at.ed.8022401046
IMUNOLÓGICOS ENVOLVIDOS NA PATOGÊNESE DA DOENÇA PERIODONTAL
Freire, J. M. D. O., Sousa, L. M. V. L., Rodrigues, Í. A., de Sousa, B. S., de Menezes, R. L. R., Nascimento, A. L. S., de Oliveira, M. M., & da Costa, I. B. (2024) · doi:10.22533/at.ed.8022401042
CUIDADOS PALIATIVOS NEONATAIS PARA A FAMÍLIA
Silva, F. A., Chady, C. S., & Dias, R. A. (2024) · doi:10.22533/at.ed.8022401045
USO DE PSICOTRÓPICOS EN CULTURAS ANCESTRALES: UN VIAJE A TRAVÉS DEL TIEMPO Y LAS TRADICIONES
de Aparicio, C. X. P., Guerrero, D. A. H., & Pazmiño, P. V. L. (2024) · doi:10.22533/at.ed.8022401041
Aberle, J., Lautenbach, A., Meyhöfer, S., Meyhöfer, S. M., Menzen, M., Selig, L., Mai, K., & Blüher, M. (2024) · Die Diabetologie · doi:10.1007/s11428-024-01169-x
Incretins and the metabolic syndrome
Karásek, D. (2024) · Vnitřní lékařství · doi:10.36290/vnl.2024.020 · Cited by 1
Tirzepaptide: A Promising Option for Treating Obesity and Overweight
Amit, M. K. S. (2024) · International Journal of Science and Research (IJSR) · doi:10.21275/sr24305143919
Medikamentöse Adipositastherapie bei Typ-2-Diabetes
Kantowski, T., Wiesch, C. S. Z., Aberle, J., & Lautenbach, A. (2024) · CME · doi:10.1007/s11298-024-3862-3
Rajcsanyi, L. S., Schmidt, J., Düerkop, S., Grote, L., Peters, T., Körner, A., Fischer‐Posovszky, P., & Hinney, A. (2024) · Diabetes aktuell · doi:10.1055/a-2325-4522
Diabète de type 2 – importance d’une approche holistique et d’un traitement précoce
(2024) · Bulletin des Médecins Suisses · doi:10.4414/bms.2024.1493605095
Boregowda, K., & Bain, S. C. (2024) · British Journal of Diabetes · doi:10.15277/bjd.2024.443
TIRZEPATIDA - UMA NOVA FARMACOTERAPIA PARA DIABETES MELITTUS TIPO 2
Fontes, L. B. A., & Souza, G. L. D. (2024) · Revista Científica Fagoc. · doi:10.61224/2525-5045.2023.1097 · Cited by 3
Manapurthu, M. G., Deepashree, C., Pradeep, R., & Nivedha, M. (2024) · Journal of Pharmaceutical and Biological Sciences · doi:10.18231/j.jpbs.2024.011 · Cited by 1
Was passiert nach Absetzen der Therapie?
Diener, H. (2024) · InFo Neurologie + Psychiatrie · doi:10.1007/s15005-024-3998-4
L’avenir des traitements du diabète
Mahmutovic, M., Berkebile, G., Guichard, C., Scheyer, N., Creton, C., & Guerci, B. (2024) · Soins · doi:10.1016/j.soin.2024.08.014
4) Update of GLP-1 Receptor Agonists
Inagaki, N. (2023) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.112.1613
Abramov, V. V., & Maksimov, M. L. (2024) · Glavvrač (Chief Medical Officer) · doi:10.33920/med-03-2407-03
Leitsymptom: Übergewicht und Adipositas
Jegodzinski, L., & Meyhöfer, S. M. (2023) · Springer Reference Medizin · doi:10.1007/978-3-642-54676-1_278-1
Surgical or medical treatment of obesity-associated type 2 diabetes-an increasing clinical conundrum
Jalleh, R. J., Jones, K. L., Islam, M. S., Cai, L. F., & Horowitz, M. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i10.2036
Situations fréquentes en médecine interne
Grange, L., Barde, F., Montardi, C., et al. (2024) · La Revue de Médecine Interne · doi:10.1016/s0248-8663(24)00776-8
Protocolo terapéutico y seguimiento del paciente con diabetes mellitus tipo 1 y obesidad
Cebada, A. B., Silva, J. B. Q., Escobar-Morreale, H. F., & Chávez, L. N. (2024) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2024.10.006
Júnior, R. A. C., Miote, A. C., Monteiro, R. V. D. C., Peçanha, A. L. S., Monteiro, L. D. C., Miote, M. D., Tasca, A. C. F., Valente, D. D. A., Miranda, I. F., Monteiro, D. D. C., et al. (2024) · International Journal of Health Science · doi:10.22533/at.ed.1594912414109
Anyiam, O., Phillips, B. E., Quinn, K., Wilkinson, D. J., Smith, K., Atherton, P. J., & IDRIS, I. R. (2024) · Clinical Nutrition · doi:10.1016/j.clnu.2024.10.033
Youth-Onset Type 2 Diabetes: An Awakening Epidemic
Enesco, A. (2024) · EMJ Diabetes · doi:10.33590/emjdiabet/pmul5630
The glucagon-like peptide-1 (GLP-1) drugs poised to conquer obesity
Yin, J., Liu, Y., & Jia, W. (2024) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2024-0417
당뇨병 치료의 진화: 관해를 향해가는 혁신적 약물치료와 첨단 관리기기의 결합
Choi, J. H., & Moon, M. K. (2024) · Public Health Weekly Report · doi:10.56786/phwr.2024.17.44.4
“Tirzepatide, a GLP-1 /glucose-dependent insulinotropic polypeptide (GIP) receptor dual agonist, demonstrated enhanced Obesity or Overweight (SURMOUNT), tirzepatide showed superior glycemic control compared to GLP-1 receptor agonists and an average weight loss of over 15 % [ 25 , 26 ].”
Impact of a Restrictive Formulary on glycemic control compared with an Open Formulary
Duong, T., Jolliff, J. C., Duvall, A., Aguirre, R., & Lash, D. B. (2024) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.2048
Prise en charge pharmacologique de l’obésité : l’apport des nouvelles classes médicamenteuses
Bauduceau, B., Bordier, L., Schlienger, J.-L., & Monnier, L. (2024) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2024.11.008 · Cited by 3
Was passiert nach Absetzen von Tirzepatid?
Diener, H. (2024) · Info Diabetologie · doi:10.1007/s15034-024-5044-5
D’Alessio, D. A., & Kahn, S. E. (2024) · Diabetes Care · doi:10.2337/dci24-0092 · Cited by 3
Semaglutide: de la moda a la evidencia científica. A propósito de una Revisión Narrativa
Bueno, E., Jara-Ruiz, E., Jara, J., Arce, M., Ramírez, A. I., & Canata, G. (2024) · Anales de la Facultad de Ciencias Médicas (Asunción) · doi:10.18004/anales/2024.057.03.102 · Cited by 2
Diabetic Nephropathy in Advanced Age Patients
Argyropoulos, C., & Roumelioti, M. (2024) · Springer eBooks · doi:10.1007/978-3-031-68460-9_8
Multi‐target Peptides for the Treatment of Metabolic Diseases
Bossart, M., & Heßler, G. (2024) · Wiley eBooks · doi:10.1002/9781394182862.ch20
大塚, 英., 小林, 俊., & 岡島, 史. (2024) · Nihon Ika Daigaku Igakkai Zasshi · doi:10.1272/manms.20.276
Maintaining Fat-Free Mass and Muscle Mass during obesity therapy with Incretin-Mimetic Drugs
Popiela, D., Urbańska, K., Stojak, Ł., Grego, M., Kwiatkowski, F., Baczewski, M., Grego, K., & Czyż, W. (2025) · Quality in Sport · doi:10.12775/qs.2025.37.57000 · Cited by 1
(2000) · Time to knit · doi:10.1016/s1155-1941(23)45189-x
Ali, F., & Farzand, M. (2025) · Kidney News · doi:10.62716/kn.000092024
The developmental trajectory of GLP-1 receptor agonists
Kou, B., & Qian, H. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27402-2.00001-2
Browning, T. E., Coy, A., Sehgal, V., Singh, S., Jakhar, N. S., Sehgal, P., & Kukreja, M. (2025) · doi:10.25259/peak_19_2024 · Cited by 1
Guduguntla, B. A., & Bazarbashi, A. N. (2025) · Digestive Diseases and Sciences · doi:10.1007/s10620-025-08887-2
Sind GLP-1-Rezeptor-Agonisten und SGLT2-Inhibitoren auch im höheren Lebensalter geeignet?
Stüdemann, S., & Engeli, S. (2025) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-2492-9440
Bischoff, S. C., Müller, M. W., Meile, T., Lange, J., Lobmann, R., Wulff, D., Kopf, D., Hebestreit, K., Nolting, B., Birk, D., et al. (2025) · Aktuelle Ernährungsmedizin · doi:10.1055/a-2377-7553
“…„glucagon-like-peptide-1“(GLP-1RA) Semaglutid (Wegovy, Novo Nordisk), sowie dem unimolekularen Koagonist am Rezeptor für das „glukoseabhängige insulinotrope Polypeptid“ (GIP-RA) und des GLP-1R (GIPR-GLP-1R-Koagonist) Tirzepatid (Mounjaro, Eli Lilly), Gewichtsreduktionen von 15-20 % möglich [18].”
Integrating social determinants of health into global approaches to early-onset type 2 diabetes
Seo, J., Rizzo, M., & Powell‐Wiley, T. M. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.108982
Role of Incretin Mimetics in the Management of Obesity
Garcha, S. C., & Kalra, S. (2025) · Springer eBooks · doi:10.1007/978-981-96-1651-0_4 · Cited by 1
GLP-1 receptor agonists: panacea or affirmation of societal failure?
Kallis, T. J., & Payne, R. (2025) · British Journal of General Practice · doi:10.3399/bjgp25x741069
Recent Updates on the Renoprotective Effects of Glucagon-Like Peptide 1 Receptor Agonists
Choi, H. S., & Bae, E. H. (2025) · Korean Journal of Medicine · doi:10.3904/kjm.2025.100.2.61
Avances farmacológicos en la lucha contra la obesidad
Portero, P. C. (2025) · Panorama actual del medicamento · doi:10.63105/49.481.1
Aberle, J., Lautenbach, A., Meyhöfer, S., Menzen, M., Selig, L., Mai, K., Blüher, M., & Terkamp, C. (2025) · Diabetes aktuell · doi:10.1055/a-2539-0910
Pompa-Mera, E. N., Valle-Hernández, M. M., Maldonado, E. R., Marín, J. A. M., Núñez-Armendáriz, M., & Gaytán‐Martínez, J. (2025) · Nutrición Hospitalaria · doi:10.20960/nh.05562 · Cited by 1
5. Weight control in type 2 diabetes management
Colagiuri, S., & Ceriello, A. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112149
McGuigan, A. (2025) · Drugs & Therapy Perspectives · doi:10.1007/s40267-025-01154-4
OBESIDADE E AUTISMO: REVISÃO SISTEMÁTICA E POSSIBILIDADES TERAPÊUTICAS EMERGENTES
Vasconcelos, R. D. (2025) · Revista Contemporânea · doi:10.56083/rcv5n4-057
Pedicino, D., & Liuzzo, G. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf236
HbA1c reduction strategies: An overview of pharmacological interventions
Upadhye, K. S., Patidar, H., Bamnia, N., & Yadav, N. K. (2025) · National Journal of Pharmacology and Therapeutics · doi:10.4103/njpt.njpt_72_24 · Cited by 2
Seifert, R., & Rauch, B. H. (2025) · Springer eBooks · doi:10.1007/978-3-662-70594-0_2
Reprise de poids après chirurgie bariatrique : intérêt des analogues GLP-1 et GIP
Bacchetta, C. (2025) · Pratiques en nutrition · doi:10.1016/j.pranut.2025.03.011
Horwitz, R. I., Otaka, S. N., Conroy, A. H., Cullen, M. R., Matory, A., Singer, B. H., & Sim, I. (2025) · The American Journal of Medicine · doi:10.1016/j.amjmed.2025.05.016 · Cited by 1
Shi, J. (2025) · Turkish Journal of Biochemistry · doi:10.1515/tjb-2024-0393
“This helps identify whether speci fi c groups show consistent Table : Risk ofbias.”
Becker, C., & Walle, H. (2025) · Diabetologie und Stoffwechsel · doi:10.1055/s-0045-1807496
Recent advances in the pharmacological treatment of obesity
Nam, G. E. (2025) · Journal of Korean Medical Association · doi:10.5124/jkma.25.0058 · Cited by 1
Zhuravlyova, L., Кривоносова, О. М., & Zhuravlyova, A. K. (2025) · PROBLEMS OF ENDOCRINE PATHOLOGY · doi:10.21856/j-pep.2025.2.07
Sind GLP-1-Rezeptor-Agonisten und SGLT2-Inhibitoren auch im höheren Lebensalter geeignet?
Stüdemann, S., & Engeli, S. (2025) · Diabetes aktuell · doi:10.1055/a-2588-6338
Xu, R. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70423
Slater, N. A. (2025) · Springer eBooks · doi:10.1007/978-3-031-88835-9_12
Pharmacological Interventions for Diabetes Management
Hay-Bradford, E. J. (2025) · Springer eBooks · doi:10.1007/978-3-031-88835-9_4
Fadini, G. P., Giaccari, A., Broglio, F., Nollino, L., Fattor, B., Anichini, R., Meregalli, G., Avogaro, A., Consoli, A., & GLIMPLES Study Investigators (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5347795
Bawazeer, N., Ganzal, S. B., Al-Hasinah, H. F., & AlRuthia, Y. S. (2025) · Healthcare · doi:10.3390/healthcare13141755 · Cited by 1
“These results align with various clinical trials that have examined the effects of Semaglutide at lower doses [23–25].”
Therapie der chronischen Niereninsuffizienz bei Diabetes mellitus
Gerdes, C., & Wolf, G. (2025) · Nephrologie aktuell · doi:10.1055/a-2536-2689
Bzoma, M., Bochenek, H., Kamiński, P., Czerepak, I., Gugulska, J., Bielicka, A., Szwarc, T., Kałwik, M., Niewczas, K., & Brzozowska, A. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3493
Traitement de la rétinopathie diabétique
Massin, P., Dupas, B., Erginay, A., Feldman, S., & Lecleire-Collet, A. (2025) · Elsevier eBooks · doi:10.1016/b978-2-294-78350-0.00008-8
Mimura, H., Oura, T., Chin, R., Hirase, T., & Shimono, D. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01775-y · Cited by 1
Park, S. J., Rosen, R. L., Muñoz‐Vergara, D., Manson, J. E., Yeh, G. Y., Wayne, P. M., & Sesso, H. D. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5363323
Aberle, J., Lautenbach, A., Meyhöfer, S., Menzen, M., Selig, L., Mai, K., Blüher, M., & Terkamp, C. (2025) · Die Diabetologie · doi:10.1007/s11428-025-01344-8
“…Gruppe mit dem kommer-ziellen Onlineprogramm signifikant höher als in der Kontrollgruppe (2,7kg vs. 1,3kg), während der Einsatz eines Aktivitätstrackers keinen zusätzlichen Nutzen (kommerzielles Onlineprogramm vs. kom-merzielles Onlineprogramm plus Aktivitätstracker: 2,7kg vs. 2,0kg) brachte [24].”
Sasidharan, S., & Lahareesh, B. L. (2025) · Global Journal of Health Sciences and Research · doi:10.25259/gjhsr_19_2025
Novel therapies – IMID Co-morbidities
Lam, T. T., So, H., & Tam, L. (2025) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2025.102089
Manchanda, Y., Desoki, R., Gardner, E. J., Perry, J. R. B., Wainscott, D. B., Stutsman, C., Langenberg, C., Coghlan, M. P., Bhatnagar, P., Ho, J. D., et al. (2025) · medRxiv · doi:10.1101/2025.08.15.25333807
The Effect of Obesity on Fertility and ART Success Among Ethnic Groups
Dahdouh, E. M., Peloquin, I. D., & Sharara, F. I. (2025) · Springer eBooks · doi:10.1007/978-3-031-96356-8_18
Incretins for obesity: closer to a nicotine patch than a silver bullet
Dippel, I., Adelman, M., Olson, K. M., Holt, A., Collins, J., Reddest, A., & Carris, N. W. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2557458
Pharmacological targets in obesity
Pavli, P., Mastorakos, G. P., & Valsamakis, G. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27370-4.00013-5
Kishimori, T., Kato, T., Wada, A., Tani, A., YAMAJI, R., Koike, J., Iwasaki, Y., Matsumoto, T., Yagi, T., & Okada, M. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.07.026 · Cited by 3
Authors' Reply: Tirzepatide and Kidney Protection in Obesity: Unanswered Questions
Heerspink, H. J. L., Bjornstad, P., Cherney, D. Z. I., & van Raalte, D. H. (2025) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000838
Skorupski, B. M., Nowak, D., Gradek, A., Sawczuk, M., Noskowicz, J., Urban, J., Konat, J., Długosz, P., Gryc, A., & Spitaleri, M. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3678
The Effectiveness of Tirzepatide on weight loss in patients with type 2 Diabetes MellitusPreprint
Olalere, M., Khawaja, M., Ndukwe, O., Khan, R., Kumar, K., Sreejith, A., Sreedharan, J., & Muttappallymyalil, J. (2025) · medRxiv · doi:10.1101/2025.09.19.25336122
“…sold under popular brand name, Ozempic, which is a GLP-1 agonist which has been proven to decrease obesity in patients with T2DM, Fries et al. study revealed that tirzepatide was not only inferior to semaglutide but also far superior in meeting greater weight loss targets and glycemic control 16 .”
INNOVATIONS IN OBESITY TREATMENT – GLP – 1 PHARMACOTHERAPY AND BARIATRIC SURGERY
Bartnik, P., Palmi, J., Bebrysz, E., Dębek-Kalinowska, K., Baran, J., Dunder, I., Koss, M., Biszewski, M., Drabik, A., & Ziomek, W. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3682
Burr, E. F., Roytman, M., Poirier, É., Kolbuszewska, M. T., Pfaus, J. G., Komisaruk, B. R., Goldstein, I., & Rubin, R. S. (2025) · Sexual Medicine · doi:10.1093/sexmed/qfaf073 · Cited by 3
Shahid, M., & Gandhi, G. Y. (2025) · Annals of Internal Medicine · doi:10.7326/annals-25-03825-jc
Dei, A., Aldigeri, R., Maglietta, G., et al. (2025) · medRxiv · doi:10.1101/2025.10.07.25337482
Revolución metabólica: redefiniendo la endocrinología con nuevas terapias basadas en incretinas
Hernández, A. R., Araujo, J. E. G., Castillo, J. F. D., Martínez, M. E. A., Cohen, N. E. Z., Navarro, A. F. U., Chavez, M. A. N., & Morales, A. L. L. (2025) · Star of Sciences Multidisciplinary Journal · doi:10.63969/tg610p62
de Souza, L. A. G., Brim, A. D. A., Filho, A. C. C. D. S., Freire, M. D. S., de Souza, R. A. G., & Peixoto, M. C. (2025) · RCMOS - Revista Científica Multidisciplinar O Saber · doi:10.51473/rcmos.v1i2.2025.1548 · Cited by 2
Xu, Y., Ji, G., Shi, C., Tan, Y., Wang, L., & Gui, Y. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112954
Maciel, J. C. H., Pereira, M. B., Serna, E. D. S., Dias, M. P., & da Silva, V. D. (2025) · Revista Omnia Saúde · doi:10.69719/ros.v8.864
Adipositas und Diabetes: Was kann man in der Praxis tun?
Weiner, S. R. (2025) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-025-5340-6
Zheng, J., Yang, J., & Yang, J. (2025) · BMJ Open · doi:10.1136/bmjopen-2025-105429 · Cited by 2
Pharmacologic Therapy for Type 2 Diabetes
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch04
Pharmacologic Therapy for Type 1 Diabetes
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch01
GLP‐1 and GIP Beyond Glycaemia: Evolutionary Roles in Energy Optimisation and Organ Protection
Tuccinardi, D., Watanabe, M., Masi, D., Gianfrilli, D., Manfrini, S., & le Roux, C. W. (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70108 · Cited by 3
Albumin-based drug/gene delivery systems
Zhang, W., Men, J., Zhou, J., & Yu, G. (2025) · Scientia Sinica Chimica · doi:10.1360/ssc-2025-0243
Metadata
- Authors
- Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K.
- Affiliations
- University of Leicester (GB)
- From the National Research Institute, Los Angeles (J.P.F.); the Diabetes Research Centre, University of Leicester, and the National Institute of Health Research Leicester Biomedical Research Centre — both in Leicester, United Kingdom (M.J.D.); the Dallas Diabetes Research Center at Medical City, Dallas (J.R.); Centro de Investigaciones Metabólicas, Buenos Aires (F.C.P.M.); and Eli Lilly, Indianapolis (L.F.L., B.K.B., B.L., X.C., K.B.).
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-08-05
- Volume
- 385
- Issue
- 6
- Pages
- 503-515
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3177122952
- Cited by
- 2,096
- References
- 25
- Citations by year
- 2026: 526 · 2025: 556 · 2024: 396 · 2023: 351 · 2022: 208 · 2021: 57
- FWCI
- 188.92
- Type
- journal article
- Language
- en
- Open access
- green
- figshare.com
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- semaglutide, type 2 diabetes, HbA1c, GLP-1 receptor agonists, GIP/GLP-1 dual agonist, non-inferiority, weight loss, gastrointestinal adverse effects, drug safety, dose comparison, glycemic control, adverse drug reactions, hypoglycemia
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Semaglutide, Blood Glucose, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Therapy, Combination, Glucagon-Like Peptides, Female, Gastric Inhibitory Polypeptide, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Male, Metformin, Middle Aged, Nausea, Weight Loss, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.